Bristol-Myers Squibb Valuation Multiples

Bristol-Myers Squibb Overview

About Bristol-Myers Squibb

Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Founded

1933

HQ

Employees

32.5K

Website

bms.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $48B

EBITDA: $17B

EV

$163B

Valuation Multiples

Multiples.vc

Start free trial

Bristol-Myers Squibb Financials

Bristol-Myers Squibb reported last 12-month revenue of $48B and EBITDA of $17B.

In the same LTM period, Bristol-Myers Squibb generated $34B in gross profit, $17B in EBITDA, and $13B in net income.

Bristol-Myers Squibb P&L

In the most recent fiscal year, Bristol-Myers Squibb reported revenue of $48B and EBITDA of $17B.

Bristol-Myers Squibb expects next 12-month revenue of XXX and NTM EBITDA of XXX

Bristol-Myers Squibb Stock Performance

Bristol-Myers Squibb has current market cap of $127B, and enterprise value of $163B.

Bristol-Myers Squibb's stock price is $62.34.

Bristol-Myers Squibb Valuation Multiples

Bristol-Myers Squibb trades at 3.4x EV/Revenue multiple, and 9.5x EV/EBITDA.

Bristol-Myers Squibb Financial Valuation Multiples

As of March 24, 2026, Bristol-Myers Squibb has market cap of $127B and EV of $163B.

Equity research analysts estimate Bristol-Myers Squibb's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Bristol-Myers Squibb has a P/E ratio of 10.1x.

Bristol-Myers Squibb Margins & Growth Rates

Bristol-Myers Squibb's revenue in the last 12 month declined by (3%).

Bristol-Myers Squibb's revenue per employee in the last FY averaged $1.5M.

Bristol-Myers Squibb's rule of 40 is 34% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Bristol-Myers Squibb's rule of X is 30% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Bristol-Myers Squibb Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Bristol-Myers Squibb M&A Activity

Bristol-Myers Squibb acquired XXX companies to date.

Last acquisition by Bristol-Myers Squibb was on XXXXXXXX, XXXXX. Bristol-Myers Squibb acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Bristol-Myers Squibb Investment Activity

Bristol-Myers Squibb invested in XXX companies to date.

Bristol-Myers Squibb made its latest investment on XXXXXXXX, XXXXX. Bristol-Myers Squibb invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).